2019
Nerve Growth Factor Improves the Outcome of Type 2 Diabetes—Induced Hypotestosteronemia and Erectile Dysfunction
Wu Y, Yang C, Meng F, Que F, Xiao W, Rao H, Wan Y, Taylor HS, Lu L. Nerve Growth Factor Improves the Outcome of Type 2 Diabetes—Induced Hypotestosteronemia and Erectile Dysfunction. Reproductive Sciences 2019, 26: 386-393. PMID: 29724155, DOI: 10.1177/1933719118773421.Peer-Reviewed Original ResearchConceptsNerve growth factorErectile dysfunctionTotal testosteroneFree testosteroneDiabetes-induced erectile dysfunctionNGF treatmentGrowth factorHyperglycemia-induced downregulationErectile Function scoreIIEF-5 scoreSerum total testosteroneType 2 diabetesMouse Leydig cellsSteroidogenic acute regulatory proteinDiabetic malesSensorimotor polyneuropathySerum testosteroneFunction scoresAcute regulatory proteinInternational IndexClinical studiesED outcomesCytochrome P450 11A1Testosterone biosynthesisLeydig cells
2009
Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II
Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, de la Longrais IA, Preti M, Menato G, Yu H. Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. European Journal Of Cancer 2009, 45: 2212-2218. PMID: 19477633, DOI: 10.1016/j.ejca.2009.05.003.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerIGF-II expressionIGF-IIOvarian cancerPrimary epithelial ovarian cancerInsulin-like growth factor IIUnfavourable prognostic markerOvarian cancer progressionPotential therapeutic targetLin-28BGrowth factor IIStem cellsIGFBP-3Overall survivalDisease progressionPrognostic markerDisease outcomeDisease featuresTherapeutic targetTumor growthTumor samplesFactor IICancer treatmentCancer progressionGrowth factor